CDKN2A and head and neck squamous cell carcinoma: Our study aims to bridge this knowledge gap by examining the prognostic implications of CDKN2A alterations in patients with recurrent and metastatic HNSCC undergoing immunotherapy, shedding light on a relatively under-explored facet of HNSCC management.